

1 **Differences in sensory nerve block between**
2 **levobupivacaine and bupivacaine at low concentrations**
3 **in humans and animals**

4

5 Short title: Selective block of nociceptive stimuli by levobupivacaine

6

7 Akiyuki Sakamoto^{1,2*}, Satoshi Tanaka¹, Takashi Ishida¹ Mikito Kawamata¹

8

9 ¹ Department of Anesthesiology and Resusitology, Shinshu University School of

10 Medicine, Matsumoto 390-8621, Japan.

11 ² Shinonoi General Hospital the Department of Anesthesiology, Nagano 388-8004,

12 Japan.

13

14 * Corresponding author

15 E-mail: akiyuki@shinonoi-hp.jp (AS)

16

17 **Author contributions**

18 Data curation: T Ishida; Formal analysis: T Ishida, Funding acquisition: A Sakamoto;

19 Investigation: A Sakamoto, S Tanaka; Methodology: S Tanaka; Project administration:

20 A Sakamoto; Resources: A Sakamoto; Software: T Ishida; Validation: S Tanaka;

21 Visualization: A Sakamoto; Writing – original draft: A Sakamoto; Writing – review &

22 editing: S Tanaka, T Ishida, M Kawamata

23 **Abstract**

24 Physiochemical properties of levobupivacaine and bupivacaine are identical, but
25 pharmacokinetic and pharmacodynamics properties differ due to stereoselective
26 interactions at the molecular sites of action. An evaluation of nerve block characteristics
27 essential for optimal clinical application. This study compared the sensory blocking
28 characteristics of levobupivacaine to bupivacaine in humans and model animals.
29 Levobupivacaine and bupivacaine were compared for sensory block efficacy using a
30 randomized, double-blinded, crossover study design. Eighteen healthy volunteers were
31 randomized to receive levobupivacaine or bupivacaine by subcutaneous injection into the
32 forearm, followed by the other drug 1 week later with injection order counterbalanced
33 across subjects. Tactile detection and mechanical pain thresholds were determined using
34 von Frey hairs and thermal pain threshold using a thermal stimulator. Effects of
35 levobupivacaine and bupivacaine, on the spiking activity of spinal dorsal horn (SDH)
36 neurons evoked by innocuous or noxious stimuli were also compared in anesthetized
37 Sprague–Dawley rats by in vivo extracellular recordings. There were no significant
38 differences in mechanical and thermal pain thresholds following levobupivacaine or
39 bupivacaine injection at 0.025%, 0.0625%, and 0.125%. There was also no significant
40 difference in tactile detection threshold following levobupivacaine or bupivacaine
41 injection at 0.125%. However, tactile detection threshold was significantly higher after
42 administration of bupivacaine at 0.025% and 0.0625% compared to equivalent doses of
43 levobupivacaine. Subcutaneous injection of bupivacaine at 0.05% also induced
44 significantly greater inhibition of SDH neuron spiking activity evoked by innocuous
45 stimuli compared to an equivalent dose of levobupivacaine, while there was no significant

46 difference in suppression of spiking activity evoked by noxious stimuli. Low-dose
47 bupivacaine induces greater suppression tactile sensation than low-dose levobupivacaine.
48 Thus, low-dose levobupivacaine demonstrates relatively greater blocking selectivity for
49 noxious over innocuous stimuli compared to low-dose bupivacaine. Levobupivacaine
50 may be advantageous for applications where pain must be suppressed but non-nociceptive
51 sensations maintained.

52

53 **Introduction**

54 Bupivacaine is a long-acting local anesthetic that has been used clinically for several
55 decades as a racemic mixture (50:50) of dextrorotatory R-(+)- and levorotatory S-(-)-
56 isomers. However, the R-(+)-isomer may contribute disproportionately to adverse effects
57 on the nervous and cardiovascular systems than the S-(-)-isomer [1-5]. Therefore,
58 levobupivacaine, the pure S-(-)-isomer of bupivacaine, has been introduced into clinical
59 practice as a safer alternative. Although the physiochemical properties of levobupivacaine
60 and bupivacaine are identical, they differ in pharmacokinetic and pharmacodynamics
61 properties due to stereoselective interactions at molecular targets [4-6].

62 Local anesthetics at sufficient concentrations can prevent impulse transmission by
63 all types of peripheral nerves, resulting in motor blockade and sensory blockade for both
64 noxious and innocuous stimuli. Complete block of motor and sensory transmission is
65 generally beneficial during surgery, while nociceptive-specific block without motor
66 paralysis or loss of innocuous sensation is often desirable in the post-operative period to
67 facilitate earlier mobilization. The motor-blocking potency of levobupivacaine is lower
68 than that of bupivacaine at the same concentration and amount when administered by
69 intrathecal and epidural routes [5, 7-10]. Recently, Uta and colleagues reported that
70 levobupivacaine also potently inhibits A δ - and C-fiber transmission but requires a
71 higher dose to suppress A β fiber transmission compared to bupivacaine as evidenced by
72 whole cell patch-clamp recordings from rat spinal dorsal horn (SDH) neurons [11].
73 Nerve fibers of the A β -type transmit tactile and pressure sensations, whereas A δ - and C-
74 fibers transmit nociception from noxious stimuli [12]. Therefore, we hypothesized that
75 levobupivacaine would produce greater nociceptive-specific block than bupivacaine, a

76 property especially useful in the outpatient surgery setting. However, these differential
77 blocking properties have not been confirmed in vivo.

78 It is of great importance to characterize the sensory block characteristics of bupivacaine
79 and levobupivacaine for optimal clinical applications. The purpose of the present study
80 was to compare the relative selectivity of racemic bupivacaine to levobupivacaine for
81 pain sensation and tactile sensation block by measuring sensory thresholds in human
82 volunteers and the spiking activity of SDH neurons in response to noxious and innocuous
83 cutaneous stimuli by in vivo single unit extracellular recordings in anesthetized rats.

84

85 **Materials and methods**

86 This study consists of two parts. In Experiment (1), we compared the effects of
87 levobupivacaine to bupivacaine on the tactile detection threshold and both mechanical
88 and thermal pain sensation thresholds following subcutaneous administration in healthy
89 human volunteers. In Experiment (2), the effects of subcutaneous levobupivacaine and
90 bupivacaine administration were compared for suppression of SDH neuron activity
91 evoked by innocuous and noxious stimuli in anesthetized rats.

92

93 **Experiment (1): Effects of subcutaneous levobupivacaine and** 94 **bupivacaine on human sensory thresholds**

95 **Subjects**

96 Experiment (1) was conducted in accordance with the principles outlined in the
97 Declaration of Helsinki and the ethical guidelines for pain research in humans of the
98 International Association for Study of Pain. All protocols were approved by the Ethics
99 Committee of Shinshu University School of Medicine, Matsumoto, Japan (document
100 number: 3252) on October 8, 2015. Experiment (1) was also registered with the
101 University Hospital Medical Information Network in Japan (number UMIN000019307)
102 on October 10, 2015. Recruitment for the study ran from October 13, 2015 to February
103 15, 2018 and conducted from October 18, 2015 to March 3, 2018 at Shinshu University
104 Hospital, Matsumoto, Japan. Written informed consent was obtained from each subject
105 before testing. A randomized, double-blinded, crossover design was implemented to
106 compare different subcutaneous doses of levobupivacaine and bupivacaine without bias.

107 Eighteen volunteers (15 male and 3 female) aged 23–46 years old were recruited at
108 Shinshu University School of Medicine. Inclusion criteria were 20 years of age or older
109 and willing to provide informed consent. Exclusion criteria were analgesic allergies, drug
110 or alcohol abuse, diabetes, neuromuscular diseases, chronic pain, and daily use of
111 analgesics.

112

113 **Study protocol**

114 A CONSORT diagram of study enrolment is presented in Fig 1. The 18 volunteers were
115 randomly assigned to receive either levobupivacaine in the first period followed by
116 bupivacaine in the second period or bupivacaine in the first period followed by
117 levobupivacaine in the second period at a 1:1 ratio (crossover design). Volunteers were
118 randomized to the levobupivacaine-first or bupivacaine-first group using the random
119 generation function in Microsoft Excel with a permuted random block size of 6. Subjects
120 were further randomly divided into three dose groups receiving 0.125%, 0.0625%, or
121 0.025% injections. These groups were administered the same dose of the other local
122 anesthetic after a 1-week washout period. The commercial 0.5% bupivacaine preparation
123 Marcaine® (AstraZeneca KK, Osaka, Japan) and the 0.5% levobupivacaine preparation
124 Popsaine® (Maruishi, Tokyo, Japan) were diluted in sterile normal saline on the test day
125 to yielded the 0.125%, 0.0625%, or 0.025% solutions for subcutaneous injection. Freshly
126 prepared solutions were injected into the anterior aspect of the left forearm at a volume
127 of 3 mL using a 25-gage needle under ultrasound guidance (S-Nerve™, SonoSite Japan
128 KK., Tokyo, Japan). The tactile detection threshold (TDT) and mechanical pain threshold
129 (MPT) were determined at the center of the injected area by applying von Frey (vF) hairs
130 of increasing stiffness (force). The TDT was measured from a baseline force of 0.16 g

131 and MPT from a baseline of 6 g. Participants were instructed to announce when touch
132 was first detected (TDT) and when the stimulus became painful (MPT). Each threshold
133 was measured three times at intervals of 10 s, and the median value was recorded for
134 analyses. The thermal pain threshold (TPT) was measured using a thermal stimulator
135 (THERMAL STIMULATOR®, Dia-medical Co., Tokyo, Japan). The thermode, a Peltier
136 element covered by a ceramic contact plate (6 mm × 6 mm), was heated at a rate of 1.0°C/s
137 from a baseline temperature of 32°C to a maximum of 47°C to prevent injury. Participants
138 were instructed to notify when thermal pain sensation was detected. Evaluators of these
139 sensory thresholds were blinded to the anesthetic administered. Measurements were
140 performed before injection and 5, 15, 30, 45, and 60 min after injection in a quiet room
141 with controlled ambient temperature (22°C–24°C) (Fig 2).

142

143 **Fig 1. CONSORT diagram illustrating the flow of participants through each phase**
144 **of the randomized crossover trial**

145 **Fig 2. Schematic diagram of Experiment (1) in humans.**

146 Tactile and mechanical pain thresholds were determined using von Frey (vF) hairs applied
147 for 5 s, while thermal pain threshold was measured using a thermal stimulator
148 (THERMAL STIMULATOR®, Dia-medical Co., Tokyo, Japan) heated at 1°C/min from
149 32°C to a maximum of 47°C. All thresholds were measured at baseline and again at the
150 same site and times following subcutaneous injection of local anesthetic (LA).

151

152 To control for possible carryover effects from one injection to the next, the total
153 scores for each period were compared between two sequence groups using an independent
154 samples t-test. Furthermore, the effect of each period was examined by comparing the

155 thresholds in the first period with the thresholds in the second period using paired-sample
156 t-tests [13].

157

158 **Experiment (2): Effects of subcutaneous levobupivacaine and** 159 **bupivacaine on spinal dorsal horn transmission in anesthetized** 160 **rats**

161 All animal care and study protocols were approved by the Shinshu University School of
162 Medicine Animal Care and Use Committee (no. 021118) and conducted in accordance
163 with the guidelines of the National Institutes of Health. Seven-week-old male Sprague–
164 Dawley rats weighing 180–220 g were housed under controlled temperature (22–23°C),
165 humidity 40%–60%, and light/dark cycle (12-hour/12-hour) with ad libitum access to
166 food and water.

167 Prior to neuronal recordings, rats were anesthetized with 3% sevoflurane in oxygen.
168 A middle vertical incision was made over the dorsum and the underlying paraspinous
169 musculature was detached from the spinous processes and dorsal aspects of vertebrae
170 from T10 to L3. Dorsal laminectomies were performed across T12–L1 to expose the
171 lumbar intumescence. The rat was then placed into a stereotaxic frame (Model ST-7,
172 Narishige, Tokyo, Japan) and secured using vertebral clamps and ear bars. After removing
173 the dura, the surface of the spinal cord was irrigated at 10 mL/min with Krebs's solution
174 (in mM, NaCl, 117; KCl, 3.6; CaCl₂, 1.2; NaH₂PO₄, 1.2; glucose, 11; NaHCO₃, 25 mM)
175 aerated with 95% O₂–5% CO₂. Body temperature was maintained at 36°C–38°C using an
176 infrared heat lamp and thermo-controlled heat pad based on feedback from a rectal

177 thermometer.

178 Extracellular recordings from single neurons were acquired using a tungsten
179 electrode (10–12 M Ω ; FHC Inc., Brunswick, ME) inserted in the deep dorsal horn of the
180 lumbar spinal cord. We identified neurons (single units) according to the mechanical
181 receptive fields (RF) of the hindpaw. Extracellular action potentials were amplified
182 ($\times 20000$ – 50000), band-pass filtered between 300–3000 Hz, digitized (CED 1401;
183 Cambridge Electronic Design, Cambridge, UK), and stored on an IBM-AT personal
184 computer (Think Pad; IBM Japan, Tokyo). Spike trains were analyzed using Spike 2
185 (Cambridge Electronic Design).

186 Neurons that responded to both an innocuous stimulus (light touch with a camel-hair
187 brush) and a noxious stimulus (pinch force of 250 g/mm² using an arterial clip) were
188 classified as wide-dynamic-range (WDR), those responsive to noxious but not non-
189 noxious stimuli as high-threshold, and those responsive to low- but not high-intensity
190 stimulation as low-threshold (LT). Only WDR and LT neurons were examined in this
191 study. Consistent with previous reports, all WDR neurons included in the analysis
192 responded to greater stimulus intensities with a graded increase in spike frequency [14],
193 while LT neurons responded only to light mechanical (innocuous) stimuli from a 10 g or
194 lighter vF hair [15]. Therefore, the pinch stimulus was used throughout as a strong
195 noxious stimulus and a 10 g vF hair as a weak noxious stimulus. The responses of
196 individual WDR neurons to stimulation by 4 g and 10 g vF hairs, a brush, and pinch at
197 the center of the RF were recorded in order. Similarly, the responses of LT neurons to
198 stimulation by a 4 g vF hair and a brush at the center of the RF were recorded in order.
199 For measurement of levobupivacaine and bupivacaine effects on these responses, rats
200 were randomly allocated to receive a 500-microL subcutaneous injection of 0.05%

201 levobupivacaine, 0.05% bupivacaine, or equal-volume saline using a 30-gage needle
202 targeted to the center of the RF. The responses to punctate mechanical stimulation using
203 4 or 10 g vF hairs with sufficient force to bend the hairs for 5 s were recorded.
204 Additionally, the responses to one stroke from a camel-hair brush and a pinch stimulation
205 from an arterial clip for 5 s were recorded. The neuronal responses to mechanical stimuli
206 were recorded 5, 10, 20, 30, 60, and 90 min after injection by investigators blinded to
207 group allocation (levobupivacaine, bupivacaine, or saline).

208

209 **Statistical analyses**

210 Prior to Experiment (1), a statistical power analysis was performed using G*Power,
211 version 3.1, with TDT as the primary outcome. Wallace and coworkers reported a TDT
212 of 3.86 ± 0.38 mN (mean \pm SD) at the arm [16]. Therefore, when levobupivacaine does
213 not change TDT while bupivacaine increases TDT by 20% at the same concentration, a
214 sample size of 6 is required for a type I error of 0.05 and power of 0.8. As we tested three
215 doses (0.125%, 0.0625%, and 0.025%), 18 people were recruited. Mean responses in each
216 group were first log-transformed. Results are presented as box-and-whisker plots showing
217 the median with first and third quartiles as well as the 10th and 90th percentiles. Baseline
218 responses were compared among groups using the Kruskal–Wallis H-test with Dunn’s
219 post-hoc tests for multiple comparisons, while anesthesia-induced changes were
220 compared by Mann–Whitney U-test with Bonferroni correction for multiple comparisons.
221 The sample size calculation for Experiment (2) was based on a previous study recording
222 changes in the firing rates of SDH neurons evoked by local anesthetics in anesthetized
223 animals [17]. All data are presented as mean \pm SD. Baseline firing frequencies were

224 compared among groups by Kruskal–Wallis H-test with Dunn’s post-hoc tests for
225 pairwise comparisons, while changes induced by bupivacaine and levobupivacaine were
226 compared by Mann–Whitney U-test with Bonferroni correction. All statistical analyses
227 were performed using GraphPad Prism version 9.0 (GraphPad Software, San Diego, CA).
228 For all statistical tests, $P < 0.05$ (two-tailed) was considered statistically significant.
229

230 **Results**

231 **Experiment (1): Subcutaneous injection of low-dose** 232 **bupivacaine induced greater suppression of tactile sensation** 233 **than low-dose levobupivacaine in human volunteers**

234 **Patient characteristics**

235 All 18 healthy volunteers completed the study without major side effects. Demographic
236 characteristics are summarized in Table 1.

237 **Table 1. Demographic characteristics of human volunteers**

	male	female	total
N	15	3	18
Age (y.o.)	33 ± 7	27 ± 4	32 ± 7
Height (cm)	169 ± 6	155 ± 10	167 ± 9
Weight (kg)	65 ± 13	45 ± 9	61 ± 15

238 Data are presented as mean ± standard deviation.

239 **Carryover and period effects**

240 There were no significant differences in baseline TDT, MPT, and TPT, and no significant
241 differences in threshold changes at 15 min post-administration between periods and
242 anesthetics at equivalent doses (Supplementary Table S1), indicating that changes in TDT,
243 MPT, and TPT induced by bupivacaine or levobupivacaine administration in the first
244 period had disappeared by the start of the second period. Therefore, pooled data from the
245 first and second periods were used to investigate the effects of levobupivacaine and
246 bupivacaine on all outcomes.

247

248 **Effects of levobupivacaine and bupivacaine on sensory thresholds**

249 There were no significant differences in the TDT (Fig 3A), MPT (Fig 3B), and TPT (Fig
250 3C) at baseline between anesthetic groups. As expected, TDT increased significantly after
251 subcutaneous administration of both levobupivacaine and bupivacaine at concentrations
252 of 0.125%, 0.0625%, and 0.025%. There was no significant difference in TDT between
253 anesthetic groups at 0.125%. However, TDT was significantly higher 5 and 15 min after
254 subcutaneous administration of 0.0625% bupivacaine compared to the same
255 levobupivacaine concentration at 5 and 15 min post-injection ($P = 0.029$ and $P = 0.026$),
256 and 5, 15, 30 and 45 min after administration of 0.025% bupivacaine compared to the
257 same levobupivacaine concentration and post-administration times ($P = 0.002$, $P = 0.002$,
258 $P = 0.002$, and $P = 0.026$, respectively). Both levobupivacaine and bupivacaine also
259 significantly increased the MPT at all concentrations tested as quantified by mean vF hair
260 force, and the TPT produced by contact heat at 5 min after injection compared to before
261 injection, without significant differences between drugs at equivalent concentrations and
262 post-injection times (Figs 3B and 3C).

263

264 **Fig 3. Changes in tactile and pain thresholds in human volunteers following** 265 **subcutaneous bupivacaine and levobupivacaine injections.**

266 (A, B) Tactile detection threshold (TDT) (A) and mechanical pain threshold (MPT) (B)
267 measured using von Frey hairs. (C) Thermal pain threshold (TPT) measured by a
268 thermal stimulator. The TDT was significantly higher (tactile response less sensitive)
269 following bupivacaine injection at concentrations of 0.025% and 0.0625% compared to
270 equal-dose levobupivacaine (A), while MPT and TPT did not differ between LAs at any

271 concentrations tested (B, C). *Arrows* indicate the cutoffs (B, C), and the dotted line
272 indicates the baseline level (A, B). * $P < 0.05$ between bupivacaine and
273 levobupivacaine, # $P < 0.05$ vs. baseline.

274

275 **Experiment (2): Subcutaneous injection of bupivacaine**
276 **induced greater suppression of SDH neuron activity evoked by**
277 **innocuous stimulation than equal-dose levobupivacaine in**
278 **anesthetized rats**

279 A total of 37 neurons were identified from the T13 to L1 SDH of 37 anesthetized rats, of
280 which 19 were classified as WDR and the remaining 18 as LT neurons. Of these, complete
281 baseline and post-injection spike recordings were obtained from 13 WDR and 13 LT
282 neurons for analysis. The average of depth of the electrode tip position below the dorsal
283 spinal cord surface was $745 \pm 103 \mu\text{m}$ for WDR neurons and $432 \pm 70 \mu\text{m}$ for LT neurons,
284 consistent with the known anatomic distribution.

285 **Effects of bupivacaine and levobupivacaine on WDR neuron activity**
286 **evoked by innocuous and noxious stimuli**

287 Figs 4A and 5A show typical spike discharge patterns of WDR neurons in response to
288 noxious stimuli (pinch and 10 g vF hair) and innocuous mechanical stimuli (brush and 4
289 g vF hair) within corresponding receptive fields at baseline and 10, 30, and 60 min after
290 subcutaneous administration of levobupivacaine or bupivacaine, respectively, while Figs
291 4B and 5B show the mean changes. Both levobupivacaine and bupivacaine at 0.05%
292 significantly inhibited the spiking responses of WDR neurons induced by noxious stimuli

293 without significant difference (Fig 4B). However, the inhibitory effects of bupivacaine
294 on the responses of WDR neurons to (innocuous) brush and 4 g vF between 10 and 60
295 min were significantly stronger than those of levobupivacaine (brush, 5 min $P = 0.016$,
296 10 min $P = 0.016$, 20 min $P = 0.008$, 30 min $P = 0.008$, 60 min $P = 0.016$; 4g vF, 20 min
297 $P = 0.032$, 30 min $P = 0.008$, 60 min $P = 0.008$) (Fig 5B), consistent with the effects
298 observed on tactile thresholds in humans.

299

300 **Fig 4. Both bupivacaine and levobupivacaine strongly suppressed the spiking**
301 **responses of wide dynamic-range neurons to noxious stimuli in anesthetized rats.**

302 (A) Typical spiking responses of wide dynamic-range (WDR) neurons to noxious
303 stimuli (pinch and 10 g von Frey hair) at baseline and after subcutaneous administration
304 of bupivacaine or levobupivacaine (both 0.05%). (B) Mean changes in spiking response
305 to noxious stimuli after subcutaneous administration of bupivacaine ($n = 5$),
306 levobupivacaine ($n = 5$), and saline ($n = 3$).

307

308 **Fig 5. Bupivacaine suppressed the spiking response of wide-dynamic-range neurons**
309 **to innocuous stimuli more potently than levobupivacaine in anesthetized rats.**

310 (A) Typical responses of wide-dynamic-range (WDR) neurons to innocuous stimuli
311 (brush and 4 g von Frey hair) at baseline and after subcutaneous injection of bupivacaine
312 and levobupivacaine (A). (B) Mean changes in spiking response after subcutaneous
313 injection of bupivacaine ($n = 5$), levobupivacaine ($n = 5$), and saline ($n = 3$). The
314 suppression of firing was stronger after administration of bupivacaine. * $P < 0.05$
315 between bupivacaine and levobupivacaine, # $P < 0.05$ vs. baseline.

316

317 **Effects of bupivacaine and levobupivacaine on LT neuron activity in**
318 **response to innocuous stimuli**

319 Fig 6A shows typical discharge patterns of LT neurons in response to innocuous
320 mechanical stimuli (brush and 4 g vF hair) within the corresponding receptive fields at
321 baseline and 10, 30, and 60 min after subcutaneous administration of levobupivacaine or
322 bupivacaine, while Fig 6B shows the mean changes. The mean inhibitory effects of
323 bupivacaine on the responses of LT neurons to brush strokes 10–30 min post-injection
324 were significantly stronger than those of levobupivacaine ($P = 0.016$ at 10 min, $P = 0.008$
325 at 20 min, $P = 0.016$ at 30 min) (Fig 6B). Similarly, the inhibitory effects of bupivacaine
326 on the responses of LT neurons to 4 g vF at 10 and 20 min post-injection were
327 significantly stronger than those of levobupivacaine ($P = 0.032$ at 10 min, $P = 0.008$ at 20
328 min) (Fig 6B), again consistent with the effects observed on tactile thresholds in humans.

329

330 **Fig 6. Bupivacaine suppressed the spiking response of low-threshold neurons to**
331 **innocuous stimuli more potently than levobupivacaine in anesthetized rats.**

332 (A) Typical responses of low-threshold (LT) neurons to innocuous stimuli (brush and 4
333 g von Frey hair) at baseline and after subcutaneous administration of bupivacaine and
334 levobupivacaine. (B) Mean changes in spiking response after subcutaneous
335 administration of bupivacaine ($n = 5$), levobupivacaine ($n = 5$), and saline ($n = 3$). The
336 suppression of firing was stronger after administration of bupivacaine. * $P < 0.05$
337 between bupivacaine and levobupivacaine, # $P < 0.05$ vs. baseline.

338

339 **Discussion**

340 The major findings of this study are as follows. (1) In human volunteers, both 0.125%
341 bupivacaine and 0.125% levobupivacaine increased pain and tactile thresholds in
342 response to vF hairs and heat stimuli, while 0.025% and 0.0625% levobupivacaine
343 enhanced pain thresholds but not thresholds for detection of innocuous stimuli. In contrast,
344 bupivacaine at the same low concentrations enhanced thresholds to both noxious and
345 innocuous stimuli. In other words, low-dose bupivacaine suppressed sensation to
346 innocuous stimuli more powerfully than levobupivacaine. (2) In extracellular in vivo
347 recordings from rat SDH neurons, both 0.05% bupivacaine and 0.05% levobupivacaine
348 suppressed the spiking responses to noxious stimuli (from a 10 g vF hair and clamping)
349 with equal efficacy similarly. On the other hand, the inhibitory effects of bupivacaine on
350 the responses of LT neurons to 4 g vF were significantly stronger than those of
351 levobupivacaine. To our knowledge, this is the first study demonstrating that low
352 concentrations of bupivacaine and levobupivacaine have distinct anesthetic effects in
353 humans, with levobupivacaine suppressing nociceptive mechanical and thermal
354 sensations as effectively as bupivacaine but preserving innocuous tactile sensation. This
355 differential effect on sensation in humans is in accord with the distinct effects of these
356 two LAs on the spiking responses of rat SDH neurons to innocuous and noxious stimuli.
357 Thus, this study provides a plausible mechanism for the differential effects of bupivacaine
358 and levobupivacaine on tactile sensation and nociception, and further suggests that low-
359 dose levobupivacaine can suppress pain as effectively as bupivacaine but without
360 producing a numbing sensation that may delay post-operative mobilization.

361 Sensory threshold measurements in humans revealed no significant differences

362 between bupivacaine and levobupivacaine at 0.125%, in accord with previous clinical
363 studies reporting no significant differences in post-operative pain and motor block
364 between bupivacaine and levobupivacaine at 0.25% and 0.5% [18, 19]. Indeed, all three
365 of these doses are above the 95% effective dose (ED₉₅), so no substantial differences are
366 expected [20, 21]. At lower doses, however, levobupivacaine appears less effective than
367 bupivacaine for blocking peripheral sensory fibers mediating tactile sensation, but
368 roughly as effective for blocking nociceptive fibers.

369 The pricking pain sensation caused by stiff von Frey hairs is mainly transmitted by
370 A δ -fibers [22], while the heat pain sensation is transmitted by both A δ - and C-fibers [23].
371 The tactile sensation from softer von Frey hairs is transmitted by A β -fibers [24]. The SDH
372 contains neurons that respond differently to these inputs, including WDR neurons that
373 respond to stimuli of different intensities, ranging from gentle to painful [25]. Conversely,
374 LT neurons respond only to innocuous stimuli, mainly via A β -fibers [26]. In the present
375 study, 0.025% and 0.0625% levobupivacaine inhibited painful sensation but not tactile
376 sensation in humans, while 0.05% levobupivacaine suppressed WDR neuron responses
377 to noxious stimuli but not LT neuron responses to innocuous stimuli. These results
378 suggest that levobupivacaine at low doses preferentially blocks A δ - and C-fiber
379 transmission, resulting in greater relative nociceptive-specificity. Uta and colleagues also
380 reported that L-bupivacaine (levobupivacaine) preferentially inhibited the firing of
381 nociceptive neurons, while D-bupivacaine blocked the firing of nociceptive and non-
382 nociceptive neurons with roughly equal efficacy as evidenced by electrophysiological
383 analysis of rat dorsal root ganglion neurons in vitro and spinal transmission in vivo [11].

384 Levobupivacaine and bupivacaine are optical isomers with identical dissociation
385 constants, molecular weights, and liposolubility, key factors determining the activities of

386 conventional local anesthetics [27]. Both compounds also target sodium channels.
387 However, nine sodium channel subtypes have been identified (Nav 1.1–1.9), so
388 differential fiber block may result from variations in channel subtype block efficacy
389 combined with unique expression patterns among fiber types. Tetrodotoxin (TTX)-
390 resistant Nav 1.8 and 1.9 are expressed at high levels in (nociceptive) A δ - and C-fibers
391 [28-30], and it has been reported that levobupivacaine has a higher affinity for TTX-
392 resistant than TTX-sensitive sodium channels. In contrast, bupivacaine has shown no
393 difference in affinity between tetrodotoxin-sensitive and tetrodotoxin-resistant sodium
394 channels [11, 31]. Thus, the differences in sensory block characteristics between
395 bupivacaine and levobupivacaine may stem from differential blockade of TTX-sensitive
396 and -resistant voltage-gated sodium channels.

397 Suppression of tactile sensation from innocuous stimuli (a brush and vF 4 g) differed
398 between bupivacaine and levobupivacaine at 0.0625%, a concentration lower than
399 commonly used in clinical practice [1, 32] and thus not fully investigated for sensory
400 blocking properties. The concentration of local anesthetic decreases with distance from
401 the injection site, so an alternative explanation for these results is that the area of tactile
402 sensory block by levobupivacaine is smaller than that by bupivacaine at the same dose
403 and concentration. However, the equal efficacy against nociceptive stimuli mediated by
404 axons within the same fiber bundles suggests that this is unlikely.

405 The present study has several limitations. First, different noxious stimuli were used
406 in human and rat experiments (thermal vs. pinch) as the thermal stimulator probe was too
407 large for the rat hindpaw. Second, the vF hair stiffness was limited to 300 g and the heat
408 stimulus to 47°C in human experiments to prevent skin damage, which may have also
409 differentially influenced the analgesic effects of bupivacaine and levobupivacaine.

410 However, the recovery from levobupivacaine analgesia tended to be similar or slower
411 than recovery from bupivacaine (Fig 3). Therefore, it is unlikely that the analgesic
412 efficacy of levobupivacaine is inherently inferior to that of bupivacaine.

413

414 **Conclusion**

415 We demonstrate that low-dose levobupivacaine can preferentially block the transmission
416 of nociceptive information without affecting the transmission of innocuous tactile
417 information, while bupivacaine blocks both with roughly equal efficacy. Therefore,
418 levobupivacaine may be a better choice for applications requiring pain suppression but
419 maintenance of tactile sensation.

420

421 **Acknowledgments**

422 We would like to thank Dr. Masahiro Sakata (Research Planning & Drug Discovery
423 Research, Research Laboratories, Maruho Co., LTD.) for technical assistance with the *in*
424 *vivo* electrophysiological recordings.

425

426

427 **References**

- 428 1. Burlacu CL, Buggy DJ. Update on local anesthetics: focus on levobupivacaine.
429 *Ther Clin Risk Manag.* 2008;4: 381-392. doi: [10.2147/tcrm.s1433](https://doi.org/10.2147/tcrm.s1433).
- 430 2. Dillane D, Finucane BT. Local anesthetic systemic toxicity. *Can J Anesth.*
431 2010;57: 368-380.
- 432 3. Guinet P, Estebe JP, Ratajczak-Enselme M, Bansard JY, Chevanne F, Bec D, et
433 al. Electrocardiographic and hemodynamic effects of intravenous infusion of bupivacaine,
434 ropivacaine, levobupivacaine, and lidocaine in anesthetized ewes. *Reg Anesth Pain Med.*
435 2009;34: 17-23. doi: [10.1097/AAP.0b013e31819338e2](https://doi.org/10.1097/AAP.0b013e31819338e2).
- 436 4. Tsuchiya H, Ueno T, Mizogami M. Stereostructure-based differences in the
437 interactions of cardiotoxic local anesthetics with cholesterol-containing biomimetic
438 membranes. *Bioorg Med Chem.* 2011;19: 3410-3415.. doi: [10.1016/j.bmc.2011.04.030](https://doi.org/10.1016/j.bmc.2011.04.030).
- 439 5. Heppolette CAA, Brunnen D, Bampoe S, Odor PM. Clinical pharmacokinetics
440 and pharmacodynamics of levobupivacaine. *Clin Pharmacokinet.* 2020;59: 715-745. doi:
441 [10.1007/s40262-020-00868-0](https://doi.org/10.1007/s40262-020-00868-0).
- 442 6. Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, et al.
443 Molecular mechanisms of the inhibitory effects of bupivacaine, levobupivacaine, and
444 ropivacaine on sarcolemmal adenosine triphosphate-sensitive potassium channels in the
445 cardiovascular system. *Anesthesiology.* 2004;101: 390-398. doi: [10.1097/00000542-](https://doi.org/10.1097/00000542-200408000-00020)
446 [200408000-00020](https://doi.org/10.1097/00000542-200408000-00020).
- 447 7. Atiénzar MC, Palanca JM, Torres F, Borràs R, Gil S, Esteve I. A randomized
448 comparison of levobupivacaine, bupivacaine and ropivacaine with fentanyl, for labor
449 analgesia. *Int J Obstet Anesth.* 2008;17: 106-111.. doi: [10.1016/j.ijoa.2007.10.003](https://doi.org/10.1016/j.ijoa.2007.10.003).

- 450 8. Camorcia M, Capogna G, Berritta C, Columb MO. The relative potencies for
451 motor block after intrathecal ropivacaine, levobupivacaine, and bupivacaine. *Anesth*
452 *Analg.* 2007;104: 904-907. doi: [10.1213/01.ane.0000256912.54023.79](https://doi.org/10.1213/01.ane.0000256912.54023.79).
- 453 9. Lacassie HJ, Columb MO. The relative motor blocking potencies of bupivacaine
454 and levobupivacaine in labor. *Anesth Analg.* 2003;97: 1509-1513.
- 455 10. Hakan Erbay R, Ermumcu O, Hanci V, Atalay H. A comparison of spinal
456 anesthesia with low-dose hyperbaric levobupivacaine and hyperbaric bupivacaine for
457 transurethral surgery: a randomized controlled trial. *Minerva Anesthesiol.* 2010;76: 992-
458 1001.
- 459 11. Uta D, Koga K, Furue H, Imoto K, Yoshimura M. L-bupivacaine inhibition of
460 nociceptive transmission in rat peripheral and dorsal horn neurons. *Anesthesiology.*
461 2021;134: 88-102. doi: [10.1097/ALN.0000000000003596](https://doi.org/10.1097/ALN.0000000000003596).
- 462 12. Price DD, Dubner R, Hu JW. Trigeminothalamic neurons in nucleus caudalis
463 responsive to tactile, thermal, and nociceptive stimulation of monkey's face. *J*
464 *Neurophysiol.* 1976;39: 936-953. doi: [10.1152/jn.1976.39.5.936](https://doi.org/10.1152/jn.1976.39.5.936).
- 465 13. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials:
466 part 18 of a series on evaluation of scientific publications. *Dtsch Ärztebl Int.* 2012;109:
467 276-281. doi: [10.3238/arztebl.2012.0276](https://doi.org/10.3238/arztebl.2012.0276).
- 468 14. Zahn PK, Brennan TJ. Incision-induced changes in receptive field properties of
469 rat dorsal horn neurons. *Anesthesiology.* 1999;91: 772-785. doi: [10.1097/00000542-](https://doi.org/10.1097/00000542-199909000-00030)
470 [199909000-00030](https://doi.org/10.1097/00000542-199909000-00030).
- 471 15. Reali C, Fossat P, Landry M, Russo RE, Nagy F. Intrinsic membrane properties
472 of spinal dorsal horn neurones modulate nociceptive information processing in vivo. *J*
473 *Physiol.* 2011;589: 2733-2743.

- 474 16. Wallace MS, Laitin S, Licht D, Yaksh TL. Concentration-effect relations for
475 intravenous lidocaine infusions in human volunteers: effects on acute sensory thresholds
476 and capsaicin-evoked hyperpathia. *Anesthesiology*. 1997;86: 1262-1272. doi:
477 [10.1097/00000542-199706000-00006](https://doi.org/10.1097/00000542-199706000-00006).
- 478 17. Sagar DR, Kendall DA, Chapman V. Inhibition of fatty acid amide hydrolase
479 produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. *Br J*
480 *Pharmacol*. 2008;155: 1297-1306. doi: [10.1038/bjp.2008.335](https://doi.org/10.1038/bjp.2008.335).
- 481 18. Ilham C, Bombaci E, Yurtlu S, Çolakoğlu S. Efficiency of levobupivacaine and
482 bupivacaine for supraclavicular block: a randomized double-blind comparative study.
483 *Braz J Anesthesiol*. 2014;64: 177-182
- 484 19. Koch T, Fichtner A, Schwemmer U, Standl T, Volk T, Engelhard K, et al.
485 Levobupivacaine for epidural anaesthesia and postoperative analgesia in hip surgery: a
486 multi-center efficacy and safety equivalence study with bupivacaine and ropivacaine.
487 *Anaesthesist*. 2008;57: 475-482. doi: [10.1007/s00101-008-1357-3](https://doi.org/10.1007/s00101-008-1357-3).
- 488 20. Bouvet L, Da-Col X, Chassard D, Daléry F, Ruynat L, Allaouchiche B, et al,
489 editors. ED₅₀ and ED₉₅ of intrathecal levobupivacaine with opioids for Caesarean
490 delivery. *Br J Anaesth*. 2011;106: 215-220.
- 491 21. Ginosar Y, Mirikatani E, Drover DR, Cohen SE, Riley ET. ED50 and ED95 of
492 intrathecal hyperbaric bupivacaine coadministered with opioids for cesarean delivery.
493 *Anesthesiology*. 2004;100: 676-682. doi: [10.1097/00000542-200403000-00031](https://doi.org/10.1097/00000542-200403000-00031).
- 494 22. Beissner F, Brandau A, Henke C, Felden L, Baumgärtner U, Treede RD, et al.
495 Quick discrimination of A(delta) and c fiber mediated pain based on three verbal
496 descriptors. *PLOS ONE*. 2010;5: e12944.
- 497 23. Angst MS, Tingle M, Phillips NG, Carvalho B. Determining heat and

- 498 mechanical pain threshold in inflamed skin of human subjects. *J Vis Exp.* 2009;23.
- 499 24. Ackerley R, Backlund Wasling H, Liljencrantz J, Olausson H, Johnson RD,
500 Wessberg J. Human C-tactile afferents are tuned to the temperature of a skin-stroking
501 caress. *J Neurosci.* 2014;34: 2879-2883. doi: [10.1523/jneurosci.2847-13.2014](https://doi.org/10.1523/jneurosci.2847-13.2014).
- 502 25. Hanai F. Effect of electrical stimulation of peripheral nerves on neuropathic pain.
503 *Spine (Phila Pa 1976).* 2000;25: 1886-1892. doi: [10.1097/00007632-200008010-00005](https://doi.org/10.1097/00007632-200008010-00005).
- 504 26. Zimmerman A, Bai L, Ginty DD. The gentle touch receptors of mammalian skin.
505 *Science.* 2014;346: 950-954. doi: [10.1126/science.1254229](https://doi.org/10.1126/science.1254229).
- 506 27. Vladimirov M, Nau C, Mok WM, Strichartz G. Potency of bupivacaine
507 stereoisomers tested in vitro and in vivo: biochemical, electrophysiological, and
508 neurobehavioral studies. *Anesthesiology.* 2000;93: 744-755. doi: [10.1097/00000542-](https://doi.org/10.1097/00000542-200009000-00024)
509 [200009000-00024](https://doi.org/10.1097/00000542-200009000-00024).
- 510 28. Wu Y, Ma H, Zhang F, Zhang C, Zou X, Cao Z. Selective voltage-gated sodium
511 channel peptide toxins from animal venom: pharmacological probes and analgesic drug
512 development. *ACS Chem Neurosci.* 2018;9: 187-197.. doi:
513 [10.1021/acchemneuro.7b00406](https://doi.org/10.1021/acchemneuro.7b00406)
- 514 29. Tsukamoto T, Chiba Y, Wakamori M, Yamada T, Tsunogae S, Cho Y, et al.
515 Differential binding of tetrodotoxin and its derivatives to voltage-sensitive sodium
516 channel subtypes (Nav 1.1 to Nav 1.7). *Br J Pharmacol.* 2017;174: 3881-3892.. doi:
517 [10.1111/bph.13985](https://doi.org/10.1111/bph.13985)
- 518 30. Cardoso FC, Lewis RJ. Sodium channels and pain: from toxins to therapies. *Br*
519 *J Pharmacol.* 2018;175: 2138–2157. doi: [10.1111/bph.13962](https://doi.org/10.1111/bph.13962).
- 520 31. Oda A, Ohashi H, Komori S, Iida H, Dohi S. Characteristics of ropivacaine block
521 of Na⁺ channels in rat dorsal root ganglion neurons. *Anesth Analg.* 2000;91: 1213-1220.

522 doi: [10.1097/00000539-200011000-00031](https://doi.org/10.1097/00000539-200011000-00031).

523 32. Bajwa SJ, Kaur J. Clinical profile of levobupivacaine in regional anesthesia: A

524 systematic review. J Anaesthesiol Clin Pharmacol. 2013;29: 530-539. doi: [10.4103/0970-](https://doi.org/10.4103/0970-9185.119172)

525 [9185.119172](https://doi.org/10.4103/0970-9185.119172).

526

527





Figure 1

(A)



(B)





Figure 6

(A)

WDR neuron



(B)

Brush

vF 4 g




Figure 5

(A)**WDR neuron****vF 10 g****Pinch**

Levobupivacaine

Bupivacaine

Time after drug administration

0

10

30

60



0

10

30

60

5 sec

(B)**vF 10 g****Pinch**%change of discharge
frequency of WDR
neurons (%)%change of discharge
frequency of WDR
neurons (%)

● Bupivacaine ● Levobupivacaine ● Saline

Figure 4




Figure 3




Figure 2